PFF SHARES LATE BREAKING NEWS ABOUT INVESTIGATIONAL THERAPIES FOR IPF

Jun 24, 2014, 15:46 PM
Boehringer Ingelheim Announces Nintedanib Expanded Access Program (EAP) for Patients with Idiopathic Pulmonary Fibrosis

As the trusted resource for the pulmonary fibrosis community by raising awareness, providing disease education, and funding research, the Pulmonary Fibrosis Foundation shares this late breaking news.

For further information about investigational therapies for IPF, watch the recorded PFF Disease Education Awareness webinar, "Ask a Doc: Clinical Trial Update," with PFF experts discussing clinical trial results for pirfenidone, nintedanib and N-Acetylcysteine. Contact the PFF Patient Communication Center for further information, 844.TalkPFF (844.825.5733) and pcc@pulmonaryfibrosis.org.
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >